Zealand Pharma executed transactions to repurchase 205,000 shares during week 29 (July 13-17, 2026) as part of its ongoing share buy-back program authorized for up to DKK 1.3 billion. The total shares repurchased under the program now amount to 1,994,000, with Zealand Pharma holding about 4% of its share capital as treasury shares. This buy-back program, managed independently by Danske Bank, aims to support shareholder value and will continue until October 31, 2026.
Varex Imaging Corporation reported a strong Q3 earnings per share (EPS) of $0.31, surpassing analyst estimates of $0.21 by over 40%, signaling robust profitability. However, its revenue of $210.5 million fell slightly short of the expected $215.5 mil...
Par Pacific Holdings' stock has shown mixed performance recently, gaining 1.59% over the past 30 days but dropping 8.90% in the last 10 days. Analysts see a 9.37% growth potential with a target price of $78.80, suggesting upside from current levels. ...
Braveheart Bio's CFO recently purchased 27,777 shares at a total cost of $500,000. This significant insider buying suggests confidence in the company's future and may indicate that the recent IPO was successful. Investors often view such insider purc...
Capital One Financial downgraded Monday.com's stock rating to Equalweight with a new price target of $95, citing Q3 revenue guidance below analyst expectations. Monday.com forecasted Q3 revenue between $368 million and $370 million, under the consens...
Amentum Holdings is set to report its Q3 2026 earnings on August 11, with analysts expecting $0.62 EPS and $3.57 billion in revenue. The company is involved in advanced nuclear projects, including a partnership with Rolls-Royce SMR for small modular ...
